Related Experiment Video
Updated: Dec 17, 2025
10:12
Enrichment of Mammalian Tissues and Xenopus Oocytes with Cholesterol
Published on: March 25, 2020
6.5K
Cyclodextrins: Potential therapeutics against atherosclerosis
Maryam Mahjoubin-Tehran1, Petri T Kovanen2, Suowen Xu3
1Department of Medical Biotechnology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Pharmacology & Therapeutics
|June 30, 2020
Summary
Cyclodextrins show promise for treating atherosclerosis by removing excess cholesterol. These compounds offer a potential new therapy to reduce cardiovascular disease deaths.
Area of Science:
- Biochemistry
- Cardiovascular Medicine
- Pharmacology
Background:
- Atherosclerosis is a leading cause of global mortality, characterized by cholesterol accumulation in arteries.
- Current treatments for atherosclerotic cardiovascular diseases have limitations, necessitating novel therapeutic strategies.
Purpose of the Study:
- To review the therapeutic potential of cyclodextrins for atherosclerosis treatment.
- To update on recent in vitro and in vivo studies of cyclodextrins in atherosclerosis.
Main Methods:
- Cyclodextrins, cyclic oligosaccharides, form inclusion complexes with cholesterol.
- Studies explored cholesterol extraction from cells and atherosclerotic lesions using cyclodextrins.
Main Results:
- Cyclodextrins effectively entrap cholesterol, reducing its accumulation.
- In vitro and in vivo experiments demonstrate cyclodextrins' potential in managing atherosclerotic plaques.
Conclusions:
- Cyclodextrins represent a promising therapeutic approach for atherosclerosis.
- This strategy may help mitigate residual risk and reduce mortality from cardiovascular diseases.
Related Concept Videos
01:26Atherosclerosis III: Management
257
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
257
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
443
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
443
01:30Coronary Artery Disease I: Introduction
767
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
767
01:30Atherosclerosis I: Introduction
614
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
614
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
933
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
933
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.2K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.2K